On May 15, 2025, Cocrystal Pharma, Inc. (COCP) announced financial results for the first quarter of 2025 and provided a business update. Following the release of favorable safety and tolerability results for CDI-988, the company's novel, broad-spectrum protease inhibitor being developed for the treatment of noroviruses and coronaviruses, we anticipate topline results from the high-dose healthy volunteer cohort in the second quarter of 2025 and for a human challenge study as a norovirus treatment and prophylaxis later in 2025. Cocyrstal's Phase 2a influenza human challenge study of CC-42344, the company's development candidate for the treatment of pandemic and seasonal influenza A infections, is continuing after the company reported a lower than expected influenza infection rates among study participants.